CLN-978 Momentum - Tactical Long on Cullinan as Data, Cash Runway and Technicals Align
Cullinan Therapeutics (CGEM) looks like a tactical long: clinical momentum around its CD19 T-cell engager CLN-978, positive data flow from zipalertinib, and a multi-hundred-million dollar cash position reduce near-term financing risk. We outline an actionable trade with entry at $14.00, stop at $11.00 and a $22.00 target over a 180 trading-day hori…